Development of multiepitope subunit protein vaccines against Toxoplasma gondii using an immunoinformatics approach.

ABSTRACT: Approximately one-third of the world's human population is estimated to have been exposed to the parasite Toxoplasma gondii. Its prevalence is reportedly high in Ethiopia (74.80%) and Zimbabwe (68.58%), and is 40.40% in Nigeria. The adverse effect of this parasite includes a serious congenital disease in the developing fetus of pregnant women. After several efforts to eliminate the disease, only one licensed vaccine 'Toxovax' has been used to avoid congenital infections in sheep. The vaccine has been adjudged expensive coupled with adverse effects and short shelf life. The potential of vaccine to likely revert to virulent strain is a major reason why it has not been found suitable for human use, hence the need for a vaccine that will induce T and B memory cells capable of eliciting

SUBMITTER: Onile OS 

PROVIDER: S-EPMC7671309 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature